Skip to main content
OpenTrials
Completed

NCT Number: NCT01504984

Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers

The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYO-1126 and Glivec Film Coated tab 4T (400mg) when administered a single-dose to healthy male volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Severance hospital

Seoul, Seodaemun-gu, South Korea

About this study

Healthy volunteers are administrated single-dose over the period I and II (crossover) of SYO-1126 and Glivec Film Coated tab 4T (400mg) as of imatinib 400mg.

Every time before and after each medication, pharmacokinetic (PK) parameters and safety of SYO-1126 and Glivec Film Coated tab 4T (400mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between 20aged and 45aged in healthy males
  • Over 55kg and BMI: 18.5~25 kg/m2
  • Agreement with written informed consent

Exclusion criteria

  • Subject with symptoms of acute disease at the time of screening
  • Clinically significant cardiovascular system, pulmonary system, renal system, endocrine system, blood system, gastrointestinal system, nervous system, mental disease or malignant tumor
  • Subject with known for gastrointestinal disease or surgical history which affect on absorption of drug
  • An impossible one who participates in clinical trial by result of screening tests
  • Inadequate result of laboratory test AST/ALT > 1.5 x UNL Total bilirubin > 1.5 X UNL
  • Clinically significant allergic disease(Except for mild allergic rhinitis seems to be not need for medication)
  • Subject with known for hypersensitivity reaction to imatinib analog
  • Subject with known for history which drug abuse or show positive for it in screening tests
  • Previously participate in other trial within 60 days
  • Previously make whole blood donation within 60 days or component blood donation within 30 days
  • Previously have blood transfusion within 30 days
  • Not able to taking the institutional standard meal
  • Subject who have had abnormal eating which affect on the ADME of drug
  • Not able to taking the grapefruit-containing foods
  • Taking ETC(ethical the counter)medicine including oriental medicine within 14 days or taking OTC(over the counter)medicine or vitamin preparations within 7 days
  • Continued to be taking caffein(caffein>5cup/day), drinking (alcohol>30g/day) and severe heavy smoker(cigarette>1/2pack/day)
  • An impossible one who participates in clinical trial by investigator's decision including for reason laboratory test result

Treatment and study plan

SYO-1126

Drug

Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)

Other names: Imatinib 400mg

Glivec film coated tab 4T(400mg)

Drug

Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)

Other names: Imatinib 100mg, Glivec film coated tab

Primary outcomes

  1. Pharmacokinetics of the AUCt SYO-1126 anf Glivec Film coated tab 4T(400mg)

    Time frame: 0-72hr

  2. Pharmacokinetics of the Cmax SYO-1126 anf Glivec Film coated tab 4T(400mg)

    Time frame: 0-72hr

Secondary outcomes

  1. Pharmacokinetics of the AUCinf SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

  2. Evaluation of the safety of SYO-1126 and Glivec Film Coated 4T(400mg) from vital signs, physical exam, ECG, laboratory test, adverse events and so on.

    Time frame: 20~24 days

  3. Pharmacokinetics of the Tmax of SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

  4. Pharmacokinetics of the T1/2 of SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

  5. Pharmacokinetics of the CL/F of SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

Sponsors and collaborators

Lead sponsor

Samyang Biopharmaceuticals Corporation

Industry

Collaborators

  • Severance Hospital

Registry information

Official study title

An Open-label, Randomized, Single Dose, Crossover Phase I Clinical Trial to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab., 4T (400mg) in Healthy Male Volunteers

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Jan 6, 2012
Registry last updated
Jun 12, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.